Khattar Jack A. 4

What Happened Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), sold a total of 35,000 shares in open-market transactions on March 13, 2026 for aggregate proceeds of about $1,763,124. The sales were reported as: 24,138 shares at a weighted average price of $50.09 (≈ $1,209,072), 10,742 shares at a weighted average price of $51.00 (≈ $547,842), and 120 shares at $51.75 (≈ $6,210). On the same date he also acquired 12,500 shares that were transferred to him from the KBT Trust without consideration (a re-registration/transfer).

Key Details

• Transaction date: March 13, 2026; Form 4 filed March 16, 2026.
• Sales: total 35,000 shares; total proceeds ≈ $1,763,124.
  • 24,138 shares — weighted avg $50.09 (sales ranged $49.63–$50.62).
  • 10,742 shares — weighted avg $51.00 (sales ranged $50.63–$51.54).
  • 120 shares — $51.75.
• Acquisition: 12,500 shares transferred from the KBT Trust to Khattar without consideration (now owned directly).
• Some sales were made pursuant to a 10b5‑1 trading plan adopted December 12, 2025.
• Shares owned after the transactions are not specified in the filing.

Context Open‑market sales, especially those executed under a pre‑arranged 10b5‑1 plan, are commonly routine ways for insiders to diversify or raise cash and do not by themselves signal a change in view on the company. The 12,500‑share transfer from the trust is a non‑purchase transfer (not a market buy) and likewise does not necessarily indicate investment sentiment. The filing shows dates and weighted average prices and includes footnotes offering per‑trade price ranges if more detail is requested.